Michelle Doig - Nuvation Bio Independent Director
| NUVB Stock | USD 2.80 0.10 3.70% |
Insider
Michelle Doig is Independent Director of Nuvation Bio since 2019.
| Age | 46 |
| Tenure | 5 years |
| Address | 1500 Broadway, New York, NY, United States, 10036 |
| Phone | 332 208 6102 |
| Web | https://www.nuvationbio.com |
Nuvation Bio Management Efficiency
The company has return on total asset (ROA) of (0.1398) % which means that it has lost $0.1398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9554) %, meaning that it created substantial loss on money invested by shareholders. Nuvation Bio's management efficiency ratios could be used to measure how well Nuvation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.13. The current year's Return On Capital Employed is expected to grow to -0.16. The current year's Net Tangible Assets is expected to grow to about 791 M, whereas Total Current Assets are forecasted to decline to about 439.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Jeff York | Seres Therapeutics | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| David MBA | Seres Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Carl Langren | Lumos Pharma | 69 | |
| Lori CPA | Lumos Pharma | 40 | |
| MD BA | Lumos Pharma | 69 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| James JD | Eliem Therapeutics | 58 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Lisa Miller | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.14 |
Nuvation Bio Leadership Team
Elected by the shareholders, the Nuvation Bio's board of directors comprises two types of representatives: Nuvation Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvation. The board's role is to monitor Nuvation Bio's management team and ensure that shareholders' interests are well served. Nuvation Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvation Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| W Vernon, Independent Director | ||
| David Hung, President, Chief Executive Officer, Founder, Director | ||
| Michelle Doig, Independent Director | ||
| Gary Hattersley, Chief Scientific Officer | ||
| Moses Makunje, Principal Officer | ||
| Robert Bazemore, Independent Director | ||
| Jennifer Fox, Chief Financial Officer | ||
| Kerry Wentworth, Chief Officer | ||
| Daniel Welch, Independent Chair of the Board | ||
| Colleen Sjogren, Chief Officer | ||
| David Hanley, Chief Technical Operations Officer | ||
| Thomas Templeman, Senior Vice President - Pharmaceutical Operations and Quality | ||
| Moses CPA, VP Officer | ||
| Stacy Markel, Senior Vice President - Human Resources | ||
| Kathryn Falberg, Independent Director | ||
| Oleg Nodelman, Director | ||
| Kim Blickenstaff, Independent Director | ||
| Stephen Dang, VP Secretary | ||
| Junyuan Wang, CEO Director | ||
| Philippe Sauvage, Chief Officer | ||
| Sergey Yurasov, Chief Medical Officer | ||
| David MD, President, Founder |
Nuvation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuvation Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (66.16) % | ||||
| Current Valuation | 404.44 M | ||||
| Shares Outstanding | 335.57 M | ||||
| Shares Owned By Insiders | 26.85 % | ||||
| Shares Owned By Institutions | 56.30 % | ||||
| Number Of Shares Shorted | 11.32 M | ||||
| Price To Book | 1.87 X | ||||
| Price To Sales | 435.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Nuvation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nuvation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nuvation Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nuvation Bio Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.009 | Return On Assets (0.14) | Return On Equity (0.96) |
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.